Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Common Equity (2016 - 2025)

Historic Common Equity for Aytu Biopharma (AYTU) over the last 15 years, with Q4 2025 value amounting to $14.2 million.

  • Aytu Biopharma's Common Equity fell 5384.04% to $14.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.2 million, marking a year-over-year decrease of 5384.04%. This contributed to the annual value of $19.0 million for FY2025, which is 3157.02% down from last year.
  • Aytu Biopharma's Common Equity amounted to $14.2 million in Q4 2025, which was down 5384.04% from $23.2 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Common Equity registered a high of $143.2 million during Q1 2021, and its lowest value of $14.2 million during Q4 2025.
  • Moreover, its 5-year median value for Common Equity was $37.1 million (2023), whereas its average is $52.6 million.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 4478.56% in 2021, then crashed by 6779.19% in 2022.
  • Over the past 5 years, Aytu Biopharma's Common Equity (Quarter) stood at $105.5 million in 2021, then tumbled by 56.59% to $45.8 million in 2022, then decreased by 28.3% to $32.9 million in 2023, then decreased by 6.36% to $30.8 million in 2024, then tumbled by 53.84% to $14.2 million in 2025.
  • Its Common Equity was $14.2 million in Q4 2025, compared to $23.2 million in Q3 2025 and $19.0 million in Q2 2025.